Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study phase 1b study of ESB 1609 for Niemann-Pick type C disease

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study phase 1b study of ESB 1609 for Niemann-Pick type C disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ESB 1609 (Primary)
  • Indications Niemann-Pick disease type C
  • Focus Adverse reactions; Biomarker

Most Recent Events

  • 08 Jan 2020 Status changed from planning to recruiting, according to an E-Scape Bio media release.
  • 24 Dec 2019 New trial record
  • 19 Dec 2019 According to an E-Scape Bio media release, the company plans a Phase 1b study of ESB 1609 for Niemann-Pick type C disease in 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top